Showing results (71-80 of 240) with videos related to
Sort By:
Pageof 24
Cancer Chemotherapy and Pharmacology|January 1, 1997
Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administrationZ Zhan, S Scala, A Monks, et al.Methods in Molecular Medicine|March 5, 2011
Measuring MDR-1 by Quantitative RT-PCRS E Bates, Z Zhan, J Regis, et al.Cancer|June 1, 1979
Immunological skin testing and interpretation: a plea for uniformityS E Bates, J Y Suen, B L TranumAmerican Journal of Ophthalmology|February 15, 1986
Herpes zoster ophthalmicus in patients at risk for the acquired immune deficiency syndrome (AIDS)E V Sandor, A Millman, T S Croxson, et al.Breast Cancer Research and Treatment|September 14, 2016
ANG1005 for breast cancer brain metastases: correlation between <sup>18</sup>F-FLT-PET after first cycle and MRI in response assessmentC C O'Sullivan, M Lindenberg, C Bryla, et al.Oncogene|June 29, 2000
Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancerP Giannakakou, G Poy, Z Zhan, et al.Human Gene Therapy|January 1, 1991
Implantation of recombinant rat myocytes into adult skeletal muscle: a potential gene therapyA Salminen, H F Elson, L A Mickley, et al.The Journal of Clinical Investigation|April 15, 1997
Gene rearrangement: a novel mechanism for MDR-1 gene activationL A Mickley, B A Spengler, T A Knutsen, et al.Biochemical Pharmacology|December 24, 1996
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panelO Rixe, W Ortuzar, M Alvarez, et al.Journal of the National Cancer Institute|April 20, 2000
Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategyD Vandier, V Calvez, L Massade, et al.Pageof 24